STOCK TITAN

Kiniksa Pharmaceuticals International, plc (KNSA) Financials

KNSA NASDAQ
Trailing 12 months to September 30, 2026
Revenue $946.0M +58.2% YoY
Net Income $109.6M +205.1% YoY
EPS (Diluted) $1.31 +191.1% YoY
Free Cash Flow $197.2M +93.8% YoY
Market Cap $7.4B as of Nov 20, 2026
Price / Sales 7.8x on $946.0M revenue, trailing 12 months to September 30, 2026
Price / Earnings 67.3x on $109.6M net income, trailing 12 months to September 30, 2026
Price / Book 10.4x on $710.2M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Oct 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KNSA SEC filings page.

Kiniksa Pharmaceuticals International, plc (KNSA) reported $946.0M in revenue over the twelve months to Sep 30, 2026, up 58.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KNSA FY2025

Kiniksa has shifted from development-stage losses toward profitable growth, with cash generation now outpacing reported earnings.

In FY2025, operating cash flow of $138M exceeded net income of $59M, showing that reported earnings converted into cash rather than remaining mainly accounting profit. Free cash flow nearly matched operating cash flow, while receivables fell 62.6% and inventory rose 108.2%; working-capital movements also shaped the cash result.

Revenue reached $678M while SG&A rose 16.8%; top-line expansion outpaced this major overhead category. Gross margin was 88.5% and operating margin reached 11.4%, showing that more of the high-margin revenue was reaching operating profit as scale improved.

Assets reached $764M and liabilities $196M in FY2025, so expansion remained financed more by equity than obligations. The current ratio was 3.8x and liabilities were 25.7% of assets, pointing to liquidity rather than leverage as the more visible balance-sheet feature. Capital expenditures were 0.2% of revenue while free cash flow reached $136M, indicating that cash generation did not require heavy physical reinvestment.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 64 / 100
Financial Health Score 64/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Kiniksa Pharmaceuticals International, plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
29

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Kiniksa Pharmaceuticals International, plc scores 29/100 on it among other operating companies.

Growth
96

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Kiniksa Pharmaceuticals International, plc scores 96/100 on it among other operating companies.

Leverage
67

Kiniksa Pharmaceuticals International, plc carried $0.35 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2025. With no long-term debt figure for fiscal year 2025, Kiniksa Pharmaceuticals International, plc is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 67/100 among other operating companies measured the same way.

Liquidity
86

Kiniksa Pharmaceuticals International, plc held $3.79 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 3.79. Liquidity ranks operating companies on that ratio, and Kiniksa Pharmaceuticals International, plc scores 86/100 among other operating companies.

Cash Flow
73

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Kiniksa Pharmaceuticals International, plc scores 73/100 on it among other operating companies.

Returns
31

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Kiniksa Pharmaceuticals International, plc scores 31/100 on it among other operating companies.

Altman Z-Score Safe
23.56

Kiniksa Pharmaceuticals International, plc scores 23.56, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $7.4B against total liabilities of $196.0M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
7/8

Kiniksa Pharmaceuticals International, plc passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed
2.34x

For every $1 of reported earnings, Kiniksa Pharmaceuticals International, plc generates $2.34 in operating cash flow ($138.0M OCF vs $59.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$286.0M
YoY+58.1%
QoQ+17.4%

Kiniksa Pharmaceuticals International, plc generated $286.0M in revenue in Q3 2026. This represents an increase of 58.1% from the same quarter a year earlier. Against the prior quarter it is up 17.4%.

EBITDA
$54.7M
YoY+125.0%
QoQ+98.0%
5Y CAGRn/m

Kiniksa Pharmaceuticals International, plc's EBITDA was $54.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 125.0% from the same quarter a year earlier. Against the prior quarter it is up 98.0%.

Net Income
$47.3M
YoY+156.8%
QoQ+86.2%
5Y CAGRn/m

Kiniksa Pharmaceuticals International, plc reported $47.3M in net income in Q3 2026. This represents an increase of 156.8% from the same quarter a year earlier. Against the prior quarter it is up 86.2%.

EPS (Diluted)
$0.56
YoY+143.5%
QoQ+86.7%
5Y CAGRn/m

Kiniksa Pharmaceuticals International, plc earned $0.56 per diluted share (EPS) in Q3 2026. This represents an increase of 143.5% from the same quarter a year earlier. Against the prior quarter it is up 86.7%.

Cash & Balance Sheet

Free Cash Flow
$47.4M
YoY+43.5%
QoQ+1.8%

Kiniksa Pharmaceuticals International, plc generated $47.4M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 43.5% from the same quarter a year earlier. Against the prior quarter it is up 1.8%.

Cash & Debt
$81.7M
YoY-53.3%
QoQ-53.5%
5Y CAGR-15.6%

Kiniksa Pharmaceuticals International, plc held $81.7M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
79M
YoY+3.7%
QoQ+0.7%
5Y CAGR+2.7%

Kiniksa Pharmaceuticals International, plc had 79M shares outstanding in Q3 2026. This represents an increase of 3.7% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
90.3%
YoY+1.5pp
QoQ0.0pp

Kiniksa Pharmaceuticals International, plc's gross margin was 90.3% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 1.5 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.

Operating Margin
19.0%
YoY+5.7pp
QoQ+7.8pp

Kiniksa Pharmaceuticals International, plc's operating margin was 19.0% in Q3 2026, reflecting core business profitability. This is up 5.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.8 percentage points.

Net Margin
16.6%
YoY+6.4pp
QoQ+6.1pp

Kiniksa Pharmaceuticals International, plc's net profit margin was 16.6% in Q3 2026, showing the share of revenue converted to profit. This is up 6.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.1 percentage points.

Return on Equity
6.7%
YoY+3.2pp
QoQ+2.8pp
5Y change+20.9pp

Kiniksa Pharmaceuticals International, plc's quarterly ROE was 6.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 3.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.8 percentage points.

Capital Allocation

R&D Spending
$32.8M
YoY+35.7%
QoQ-19.8%
5Y CAGR+11.3%

Kiniksa Pharmaceuticals International, plc invested $32.8M in research and development in Q3 2026. This represents an increase of 35.7% from the same quarter a year earlier. Against the prior quarter it is down 19.8%.

Capital Expenditures
$180K
YoY-73.2%
QoQ-72.9%

Kiniksa Pharmaceuticals International, plc invested $180K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 73.2% from the same quarter a year earlier. Against the prior quarter it is down 72.9%.

Share Buybacks

Not reported for Q3 2026.

KNSA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KNSA quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$286.0M+58.1%$243.6M+55.4%$214.3M+55.5%$202.1M+65.0%$180.9M+61.2%$156.8M+44.3%$137.8M+72.5%$122.5M+46.9%
Cost of Revenue$27.8M+37.0%$23.6M+26.7%$20.8M+16.4%$20.9M+17.0%$20.3M+0.7%$18.6M+51.0%$17.9M+68.8%$17.9M+86.7%
Gross Profit$258.2M+60.8%$220.0M+59.2%$193.5M+61.3%$181.2M+73.1%$160.6M+74.4%$138.2M+43.5%$119.9M+73.1%$104.6M+41.8%
R&D Expenses$32.8M+35.7%$40.9M+118.1%$27.5M+42.2%$34.6M-1.7%$24.2M-7.3%$18.8M-21.9%$19.3M-26.6%$35.2M+75.6%
SG&A Expenses$65.4M+33.1%$63.9M+36.3%$61.2M+40.5%$56.8M+40.1%$49.1M+5.8%$46.9M+10.5%$43.5M+12.5%$40.5M+10.3%
Operating Income$54.2M+125.8%$27.2M+34.9%$29.3M+120.5%$19.8Mn/m$24.0Mn/m$20.2Mn/m$13.3Mn/m-$19.3M-23925.9%
EBITDA$54.7M+125.0%$27.6M+35.2%$29.7M+118.4%$20.2Mn/m$24.3Mn/m$20.4M+8004.4%$13.6Mn/m-$18.9M-3143.3%
Income Tax$11.7M+34.3%$5.7M+13.2%$10.1M+43.6%$9.1Mn/m$8.7M+58.8%$5.0M-18.8%$7.0M+105.0%-$8.1Mn/m
Net Income$47.3M+156.8%$25.4M+42.6%$22.6M+164.6%$14.2Mn/m$18.4Mn/m$17.8Mn/m$8.5Mn/m-$8.9M-135.2%
EPS (Basic)$0.61+144.0%$0.33+37.5%$0.30+150.0%$0.19n/m$0.25n/m$0.24n/m$0.12n/m-$0.12-133.3%
EPS (Diluted)$0.56+143.5%$0.30+30.4%$0.27+145.5%$0.18n/m$0.23n/m$0.23n/m$0.11n/m-$0.12-133.3%
Diluted Shares (Avg)85M+6.1%83M+7.0%82M+8.2%N/A80M+11.6%78M+9.8%76M+7.8%N/A

Not reported in any period shown, so not listed: Interest Expense.

KNSA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KNSA quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$983.2M+38.0%$896.1M+35.5%$825.3M+37.7%$763.6M+31.5%$712.3M+28.3%$661.1M+21.9%$599.3M+15.3%$580.6M+10.3%
Current Assets$750.1M+57.7%$668.6M+59.1%$594.2M+66.9%$527.2M+58.9%$475.5M+52.8%$420.3M+39.6%$355.9M+31.5%$331.8M+20.1%
Cash & Equivalents$81.7M-53.3%$175.7M-8.5%$190.0M+20.9%$165.6M-9.8%$174.9M+79.6%$192.0M+93.4%$157.1M+11.4%$183.6M+70.1%
Short-Term Investments$487.1M+174.8%$350.3M+202.6%$278.1M+150.1%$248.5M+313.8%$177.2M+40.2%$115.7M-3.1%$111.2M+53.4%$60.0M-39.0%
Inventory$108.0M+161.0%$70.9M+47.2%$73.1M+231.4%$54.9M+108.2%$41.4M+44.3%$48.2M+38.2%$22.1M-19.1%$26.4M-15.3%
Accounts Receivable$30.8M-40.5%$23.5M-26.4%$23.2M-42.0%$15.6M-62.6%$51.7M+107.9%$31.9M+56.0%$40.1M+150.5%$41.7M+96.2%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$273.1M+54.3%$242.0M+45.6%$219.6M+54.8%$196.0M+37.9%$176.9M+49.6%$166.1M+54.8%$141.8M+61.6%$142.1M+62.5%
Current Liabilities$191.9M+55.2%$171.2M+45.3%$156.6M+61.0%$139.2M+38.3%$123.6M+28.8%$117.8M+39.8%$97.3M+51.5%$100.6M+58.0%
Non-Current Liabilities$81.2M+52.2%$70.7M+46.4%$63.0M+41.3%$56.8M+37.0%$53.4M+138.9%$48.3M+109.7%$44.6M+89.1%$41.5M+74.2%
Total Equity$710.2M+32.7%$654.1M+32.1%$605.7M+32.4%$567.6M+29.5%$535.4M+22.5%$495.0M+13.8%$457.5M+5.9%$438.4M-0.1%
Retained Earnings-$366.8Mn/m-$414.1Mn/m-$439.5Mn/m-$462.1Mn/m-$476.3Mn/m-$494.8Mn/m-$512.6Mn/m-$521.1Mn/m

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

KNSA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KNSA quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$47.5M+41.2%$47.2M+68.0%$50.2M+124.9%$53.9M+187.1%$33.7Mn/m$28.1M+443.5%$22.3M+459.9%$18.8M+334.0%
Depreciation & Amortization$431K+55.6%$415K+57.8%$468K+35.7%$467K+16.8%$277K-17.8%$263K-28.7%$345K-26.0%$400K-25.9%
Stock-Based Compensation$13.1M+28.8%$11.6M+31.1%$10.1M+29.8%N/A$10.1M+29.6%$8.9M+20.5%$7.7M+7.5%N/A
Capital Expenditures$180K-73.2%$663K+301.8%$161K+62.6%$633K+228.0%$671Kn/m$165Kn/m$99K+17.9%$193K+244.6%
Free Cash Flow$47.4M+43.5%$46.5M+66.6%$50.0M+125.1%$53.3M+186.7%$33.0Mn/m$27.9M+440.3%$22.2M+469.4%$18.6M+335.2%
Investing Cash Flow-$138.6Mn/m-$73.6Mn/m-$31.9Mn/m-$70.8M-208.5%-$62.8Mn/m-$3.9Mn/m-$51.5M-301.9%$65.3Mn/m
Financing Cash Flow-$3.0M-125.2%$12.1M+13.2%$6.1M+119.4%$7.7M+257.5%$11.9M+77.9%$10.7Mn/m$2.8M-23.4%$2.1M+208.2%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

KNSA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KNSA quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin90.3%+1.5pp90.3%+2.2pp90.3%+3.3pp89.6%+4.2pp88.8%+6.7pp88.1%-0.5pp87.0%+0.3pp85.4%-3.1pp
Operating Margin19.0%+5.7pp11.2%-1.7pp13.7%+4.0pp9.8%+25.5pp13.3%+21.9pp12.9%+13.0pp9.6%+30.3pp-15.8%-15.8pp
Net Margin16.6%+6.4pp10.4%-0.9pp10.5%+4.3pp7.0%+14.3pp10.2%+21.5pp11.4%+15.0pp6.2%+28.4pp-7.2%-37.5pp
Return on Equity6.7%+3.2pp3.9%+0.3pp3.7%+1.9pp2.5%+4.5pp3.4%+6.3pp3.6%+4.5pp1.9%+6.0pp-2.0%-7.8pp
Return on Assets4.8%+2.2pp2.8%+0.1pp2.7%+1.3pp1.9%+3.4pp2.6%+4.9pp2.7%+3.4pp1.4%+4.8pp-1.5%-6.3pp
Current Ratio3.91+0.1x3.90+0.3x3.79+0.1x3.79+0.5x3.85+0.6x3.570.0x3.66-0.6x3.30-1.0x
Liabilities-to-Equity0.38+0.1x0.370.0x0.36+0.1x0.350.0x0.33+0.1x0.34+0.1x0.31+0.1x0.32+0.1x
Asset Turnover0.290.0x0.270.0x0.260.0x0.26+0.1x0.25+0.1x0.240.0x0.23+0.1x0.21+0.1x
FCF Margin16.6%-1.7pp19.1%+1.3pp23.4%+7.2pp26.4%+11.2pp18.3%+20.2pp17.8%+13.1pp16.1%+11.2pp15.2%+10.0pp

Not reported in any period shown, so not listed: Debt-to-Equity.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Kiniksa Pharmaceuticals International, plc KNSA FY2025 $677.6M $59.0M 8.7% $7.4B 64/100
Alkermes Inc. plc ALKS FY2025 $1.5B $241.7M 16.4% $7.6B 72/100
Amneal Pharmaceuticals, Inc. AMRX FY2025 $3.0B $72.1M 2.4% $7.4B 57/100
Lantheus Holdings, Inc LNTH FY2025 $1.5B $233.6M 15.2% $6.7B 73/100
Liquidia Corporation LQDA FY2025 $158.3M -$68.9M -43.5% $4.9B 64/100
Amylyx Pharmaceuticals, Inc. AMLX FY2025 $0 -$144.7M N/A $3.3B —

Frequently Asked Questions

Kiniksa Pharmaceuticals International, plc (KNSA) reported $677.6M in total revenue for fiscal year 2025. This represents a 60.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Kiniksa Pharmaceuticals International, plc (KNSA) revenue grew by 60.1% year-over-year, from $423.2M to $677.6M in fiscal year 2025.

Yes, Kiniksa Pharmaceuticals International, plc (KNSA) reported a net income of $109.6M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $59.0M, with a net profit margin of 8.7%.

Kiniksa Pharmaceuticals International, plc (KNSA) reported diluted earnings per share of $0.75 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kiniksa Pharmaceuticals International, plc (KNSA) had EBITDA of $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Kiniksa Pharmaceuticals International, plc (KNSA) had a gross margin of 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Kiniksa Pharmaceuticals International, plc (KNSA) had an operating margin of 11.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Kiniksa Pharmaceuticals International, plc (KNSA) had a net profit margin of 8.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Kiniksa Pharmaceuticals International, plc (KNSA) has a return on equity of 10.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Kiniksa Pharmaceuticals International, plc (KNSA) generated $136.4M in free cash flow during fiscal year 2025. This represents a 436.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Kiniksa Pharmaceuticals International, plc (KNSA) generated $138.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Kiniksa Pharmaceuticals International, plc (KNSA) had $763.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Kiniksa Pharmaceuticals International, plc (KNSA) invested $1.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Kiniksa Pharmaceuticals International, plc (KNSA) invested $96.9M in research and development during fiscal year 2025.

Kiniksa Pharmaceuticals International, plc (KNSA) had 77M shares outstanding as of fiscal year 2025.

Kiniksa Pharmaceuticals International, plc (KNSA) had a current ratio of 3.79 as of fiscal year 2025, which is generally considered healthy.

Kiniksa Pharmaceuticals International, plc (KNSA) had a liabilities-to-equity ratio of 0.35 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Kiniksa Pharmaceuticals International, plc (KNSA) had a return on assets of 7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Kiniksa Pharmaceuticals International, plc (KNSA) trades at 67.3x earnings, its market capitalization divided by $109.6M net income, trailing 12 months to September 30, 2026. The market capitalization is $7.4B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Kiniksa Pharmaceuticals International, plc (KNSA) trades at 7.8x sales, its market capitalization divided by $946.0M revenue, trailing 12 months to September 30, 2026. The market capitalization is $7.4B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Kiniksa Pharmaceuticals International, plc (KNSA) has an Altman Z-Score of 23.56, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Kiniksa Pharmaceuticals International, plc (KNSA) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Kiniksa Pharmaceuticals International, plc (KNSA) has an earnings quality ratio of 2.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Kiniksa Pharmaceuticals International, plc (KNSA) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top